Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of “Buy” from Analysts

Spyre Therapeutics, Inc. (NASDAQ:SYREGet Free Report) has earned an average recommendation of “Buy” from the six analysts that are currently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued a report on the stock in the last year is $33.50.

SYRE has been the subject of several research reports. BTIG Research assumed coverage on shares of Spyre Therapeutics in a research report on Wednesday, December 20th. They issued a “buy” rating and a $32.00 price target for the company. Lifesci Capital reissued an “outperform” rating on shares of Spyre Therapeutics in a report on Monday, December 4th. Stifel Nicolaus boosted their price objective on Spyre Therapeutics from $23.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, December 18th. Guggenheim started coverage on Spyre Therapeutics in a research note on Monday, December 11th. They issued a “buy” rating and a $44.00 target price for the company. Finally, Jefferies Financial Group assumed coverage on Spyre Therapeutics in a research note on Monday, December 11th. They issued a “buy” rating and a $31.00 target price for the company.

View Our Latest Stock Report on SYRE

Spyre Therapeutics Trading Down 5.9 %

Shares of SYRE stock opened at $22.54 on Thursday. The stock’s 50 day moving average is $21.81. Spyre Therapeutics has a 52 week low of $2.66 and a 52 week high of $28.66. The firm has a market cap of $91.26 million, a P/E ratio of -0.30 and a beta of 2.85.

Spyre Therapeutics Company Profile

(Get Free Report

Spyre Therapeutics, Inc, a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23.

Featured Stories

Analyst Recommendations for Spyre Therapeutics (NASDAQ:SYRE)

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.